Saturday 17 October 2026
Export IMTX’s income statement to Excel — free account
Immatics N.V.
IMTX Healthcare Biotechnology
Immatics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $54.6 million, down 67.6% from fiscal 2024. In the quarter to June 2026, revenue grew 97.7%, EPS grew 19.7% and free cash flow fell 44.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.72
0.42
−5.88%
Follow IMTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 3 | 7 | 4 | 4 | — | — | — |
P/E ratio |
0.00 | 39.50 | 0.00 | 11.43 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
6.75 | 3.26 | 0.15 | 1.46 | (2.50) | (0.42) | (1.44) | 0.65 | — |
P/S ratio |
23.53 | 4.46 | 14.78 | 3.16 | 20.56 | 13.28 | 0.00 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 5.82 | 0.00 | 0.00 | 4.85 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
5.14 | 7.13 | (0.56) | 2.00 | (11.05) | (2.43) | (4.89) | (1.47) | — |
Beneish M-Score |
(1.36) | 0.07 | 5.39 | (0.61) | (2.87) | (4.74) | (4,924.98) | — | — |
P/Operating CF |
(20.74) | (12.22) | 10.05 | (21.31) | (26.67) | (33.14) | 4.83 | 0.00 | — |
P/B ratio |
2.35 | 1.21 | 3.54 | 2.57 | 29.70 | 4.97 | 0.00 | 6.13 | — |
Price to Tangible BV |
2.35 | 1.21 | 3.57 | 2.58 | 31.42 | 5.01 | 0.00 | 6.13 | — |
EV/Sales |
16.36 | 2.94 | 10.73 | 2.30 | 16.73 | 7.96 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 10.79 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(4.47) | (2.90) | 31.78 | 3.98 | (7.11) | (3.63) | 3.39 | 0.00 | — |
EV/FCF |
(4.30) | (2.62) | (46.06) | 4.24 | (6.65) | (3.26) | 3.39 | 0.00 | — |
Quick Ratio |
8.18 | 3.57 | 1.42 | 1.41 | 1.40 | 3.44 | 1.51 | 655.30 | — |
Current Ratio |
11.72 | 9.26 | 2.87 | 3.54 | 1.60 | 3.94 | 1.79 | 266.46 | — |
Net Debt/EBITDA |
2.04 | 8.97 | 2.31 | (4.02) | 1.64 | 3.18 | 3.54 | 0.04 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.08 | 0.26 | 0.12 | 0.57 | 0.18 | 0.16 | 0.13 | 0.05 | — |
Operating CF/Net income |
0.90 | (10.38) | (0.19) | 2.67 | 0.88 | 0.37 | (2.25) | (0.66) | — |
Capex/Depreciation |
(0.55) | (1.35) | (4.26) | (0.88) | (1.08) | (1.70) | (0.55) | (0.19) | — |
Interest Coverage |
(4.96) | (29.23) | (14.45) | 3.62 | (50.00) | (6.93) | (125.05) | (213.72) | — |
| (38.00%) | 3.80% | (44.84%) | 31.24% | (166.40%) | (722.34%) | 176.20% | 106.81% | — | |
| (31.99%) | 2.52% | (21.39%) | 12.42% | (47.88%) | (117.79%) | (22.54%) | (43.13%) | — | |
ROIC |
(82.33%) | (7.14%) | (961.55%) | 28.96% | 0.00% | 0.00% | 0.00% | (565.68%) | — |
Return on Tangible Assets |
(39.05%) | 2.49% | (28.82%) | 13.20% | (138.14%) | (122.98%) | (53.13%) | (532.24%) | — |
Average Days of Receivables |
46.12 | 13.72 | 27.67 | 2.35 | 7.16 | 14.60 | 18.93 | 201.21 | — |
Research and Development Expense of Revenue |
380.87% | 95.02% | 219.76% | 61.78% | 251.92% | 214.65% | 217.31% | 901.09% | — |
Selling, General and Administrative Expense of Revenue |
106.05% | 29.81% | 70.74% | 20.90% | 97.25% | 109.38% | 63.72% | 203.34% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
31.11% | 11.32% | 38.34% | 13.06% | 75.95% | 73.44% | 4.62% | 39.20% | — |
Graham Net Nets |
0.38 | 0.73 | 0.21 | 0.33 | 0.00 | 0.17 | (0.15) | (4.55) | — |
Graham Number |
0.00 | 4.88 | 0.00 | 7.51 | 0.00 | 0.00 | 5.22 | 0.00 | — |
Earnings Yield |
(17.52%) | 2.53% | (12.13%) | 8.75% | (12.50%) | (44.42%) | (9.44%) | (6.02%) | — |
Free Cash Flow Yield |
(16.15%) | (25.12%) | (1.58%) | 17.19% | (12.23%) | (18.39%) | 20.62% | 0.00% | — |
Revenue per Share |
0.45 | 1.59 | 0.73 | 2.71 | 0.65 | 0.65 | 0.56 | 0.11 | — |
Operating CF per Share |
(1.63) | (1.62) | 0.24 | 1.57 | (1.54) | (1.78) | 2.14 | 0.63 | — |
Capex per Share |
(0.06) | (0.17) | (0.41) | (0.10) | (0.11) | (0.16) | (0.06) | (0.01) | — |
Free Cash Flow per Share |
(1.70) | (1.79) | (0.17) | 1.47 | (1.64) | (1.94) | 2.08 | 0.61 | — |
Cash per Share |
3.20 | 2.42 | 2.94 | 2.33 | 2.50 | 4.32 | 3.12 | 0.04 | — |
Shareholders Equity per Share |
4.48 | 5.88 | 3.02 | 3.34 | 0.45 | 2.17 | (1.23) | 0.15 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
4.48 | 5.88 | 3.02 | 3.34 | 0.45 | 2.17 | (1.23) | 0.15 | — |
Free Cash Flow |
(207.53) | (188.84) | (13.61) | 99.00 | (103.45) | (93.13) | 68.83 | 20.27 | — |
Working Capital |
521.57 | 607.67 | 316.92 | 285.21 | 67.51 | 178.38 | 54.70 | 1.33 | — |
Capital Expenditures |
(7.70) | (17.83) | (33.34) | (6.49) | (6.69) | (7.52) | (2.14) | (0.41) | — |
Net Current Asset Value |
481.72 | 549.98 | 178.03 | 192.28 | 1.92 | 88.60 | (51.11) | (139.49) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 13.30 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.14 | 0.11 | 0.57 | 0.04 | 0.16 | 0.24 | 0.12 | 0.11 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 18.25 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.29 | 0.24 | 0.17 | 0.52 | 0.50 | 0.56 | 0.82 | 0.48 | — |
Cash ROIC |
(22.10%) | (21.50%) | (2.84%) | 25.98% | (55.67%) | (29.87%) | 110.10% | 327.04% | — |
Accounts Receivable Turnover |
8.25 | 31.32 | 20.87 | 184.17 | 39.99 | 28.32 | 12.16 | 1.47 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
6.62 | 5.38 | 2.80 | 0.99 | 1.03 | 1.10 | 1.52 | 2.57 | — |
Average Payables |
21.85 | 24.84 | 20.52 | 13.75 | 11.90 | 8.57 | 5.94 | 6.38 | — |
Average Assets |
694.76 | 652.62 | 490.81 | 318.15 | 230.63 | 194.46 | 140.05 | 72.91 | — |
Average Common Equity |
584.87 | 432.82 | 234.10 | 126.53 | 66.36 | 31.71 | (17.92) | (29.44) | — |
Columns are period end dates